Loading
RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.
GTP-binding protein with GTPase activity, involved in the regulation of MAPK signalling pathway and thereby controlling multiple cellular processes. Regulates craniofacial development.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.93, genetic association 0.00, somatic mutation 0.88, animal model 0.30). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Endometrial Carcinoma.
In plain words · RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.
RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.
GTP-binding protein with GTPase activity, involved in the regulation of MAPK signalling pathway and thereby controlling multiple cellular processes. Regulates craniofacial development.
No product in this corpus aims at RRAS2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA RRAS2: RNA low tissue specificity; high antibody staining in 3 normal tissues; highest cancer staining testis cancer (1 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Endometrial cancer, Ovarian cancer, Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P62070; CIViC gene RRAS2; IntOGen RRAS2; Human Protein Atlas RRAS2 tissue; Open Targets ENSG00000133818 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Drivas G.T. et al, Mol. Cell. Biol, 1990, "Characterization of four novel ras-like genes expressed in a human teratocarcinoma cell line". Source.
Sources: HGNC HGNC:17271 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62070 (protein name, function text, keywords and locations (REST API)); CIViC gene RRAS2 (1 evidence items, 0 assertions, 1 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000133818 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: ovarian cancer 0.58, endometrial cancer 0.51, breast cancer 0.52 (GraphQL API, CC0)); IntOGen RRAS2 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
GTP-binding protein with GTPase activity, involved in the regulation of MAPK signalling pathway and thereby controlling multiple cellular processes. Regulates craniofacial development. Location: Cell membrane; Golgi apparatus membrane (UniProt). Locus 11p15.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Cerebellum, Cervix, Colon.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RRAS2" OR ABSTRACT:"RRAS2" OR TITLE:"RAS related 2" OR ABSTRACT:"RAS related 2" OR TITLE:"Ras-related protein R-Ras2" OR ABSTRACT:"Ras-related protein R-Ras2" OR TITLE:"TC21" OR ABSTRACT:"TC21") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RRAS2, not a curated reading list.